GO
Loading...

Pharmaceuticals

More

  • Pfizer to renew pursuit of AstraZeneca?  Wednesday, 26 Nov 2014 | 1:20 AM ET

    Pfizer has seen off its six month cooling period before it can launch another bid for AstraZeneca, but will the American drugs giant continue its pursuit?

  • Searching for relief from expensive generic drugs Tuesday, 25 Nov 2014 | 2:24 PM ET
    Senator Amy Klobuchar

    Generic drug costs have risen so much that some drugs have surpassed their equivalents in other developed countries, the New York Times reports.

  • Fighting kids' cancer... fixing a broken system  Friday, 21 Nov 2014 | 6:49 AM ET

    CNBC's Meg Tirrell, and Nancy Goodman, Kids v. Cancer founder, discuss the initiative to encourage drug companies to develop treatments for children with cancer and other rare diseases.

  • How to get cancer drugs to kids: A mother's take Friday, 21 Nov 2014 | 6:00 AM ET
    The Froman family, including Nancy Goodman, Mike Froman, and kids Ben and Sarah. They hold a photo of Jacob, who died of medulloblastoma, a rare form of brain cancer, at age 10.

    Kids facing cancer need access to promising — albeit unapproved — drugs, say these parents, who have faced the battle with their children firsthand.

  • Sanofi: Wouldn't trade our pipeline  Thursday, 20 Nov 2014 | 1:47 PM ET

    Sanofi's global R&D President Dr. Elias Zerhouni, says he wouldn't trade his company's pipeline with anybody in the industry, and discusses the upcoming drug launches.

  • Nov 20- A U.S. court has denied a request by Indian drugmaker Ranbaxy Laboratories Ltd to stop competitors from launching copies of AstraZeneca Plc's heartburn pill Nexium and Roche's antiviral, a court filing showed. Ranbaxy had filed a lawsuit against the U.S. Food and Drug Administration last week for revoking tentative approvals it gave the company to make...

  • Nov 20- A U.S. court has denied a request by Indian drugmaker Ranbaxy Laboratories Ltd to stop competitors from launching copies of AstraZeneca Plc's heartburn pill Nexium and Roche's antiviral Valcyte, a court filing showed. Ranbaxy had sought the restraining order against Dr Reddy's Laboratories and U.S. firm Endo International Plc in a lawsuit it filed...

  • Nov 20- Global pharmaceutical spending will break the trillion dollar mark in 2014, driven by high prices in the United States for novel treatments such as Gilead Sciences Inc's Sovaldi for hepatitis C and new cancer drugs, according to a study released on Thursday. Total spending on drugs will hit $1.06 trillion, an increase of 7 percent over 2013 levels,...

  • Nov 18- The estimated average cost of developing an approved new drug has more than doubled to more than $2.5 billion from a 2003 estimate by Tufts University, but critics questioned the figure and noted the school's strong financial ties to the pharmaceutical industry. The Tufts Center for the Study of Drug Development, located in Boston, in 2003 estimated the...

  • AstraZeneca trumpets strength in drug development Tuesday, 18 Nov 2014 | 3:24 AM ET
    British pharmaceutical company AstraZeneca's manufacturing site in Macclesfield, northwest England.

    AstraZeneca said it had made good progress in developing a pipeline of new drugs.

  • Outbreaks like Ebola will happen again: NIH Monday, 17 Nov 2014 | 3:57 PM ET
    File photo: A young man, dressed in a biohazard costume, stands on the corner of 546 West 147th Street in October 2014 in New York City after an American doctor carrying the ebola virus was admitted to Bellevue Hospital

    NIH's Dr. Francis Collins and Milken Institute Chairman Mike Milken make the case for medical research funding to stop outbreaks like Ebola.

  • *Novartis already has Google contact lens, smart pill deals. LONDON, Nov 17- Talent spotters from Novartis AG, charged with bringing new ideas into the organisation, are casting their net beyond biotech into the wider pool of wearable, or even edible, technology. The Swiss group has already taken tentative steps, signing a deal with Google Inc in July to develop...

  • Zoetis attractive & durable: Pro  Monday, 17 Nov 2014 | 12:35 PM ET

    Shares of Zoetis are on the move after Actavis announced it is buying Allergan. Mark Schoenbaum, Evercore ISI senior managing director, discusses if the company could be bought.

  • DEA painkiller probe targets NFL medical staffs Monday, 17 Nov 2014 | 11:46 AM ET
    Joe Horn

    DEA agents questioned medical-staff members from several NFL teams in a continuing investigation into distribution of painkillers, The NYT reports.

  • CHICAGO, Nov 17- Regeneron Corp's experimental drug alirocumab helped 10 times as many high-risk patients unable to tolerate widely-used statins get their "bad" LDL cholesterol down to target levels than Merck& Co's Zetia, according to data from a clinical trial presented on Monday. Alirocumab, developed along with French drugmaker Sanofi, belongs to a new...

  • Actavis, Allergan are a 'strategic fit'  Monday, 17 Nov 2014 | 11:40 AM ET

    Áine Slowey, senior analyst at Datamonitor Healthcare, discusses Actavis' decision to buy Allergan for $65.5 billion, saying that Actavis has demonstrated a "strong commitment" to R&D.

  • Why Allergan never engaged Valeant  Monday, 17 Nov 2014 | 9:36 AM ET

    Allergan chairman & CEO David Pyott, explains why Allergan never engaged Valeant Pharmaceuticals and what's next for the newly combined companies.

  • Actavis CEO: Huge commitment to R&D  Monday, 17 Nov 2014 | 9:32 AM ET

    CNBC's Jim Cramer speaks to Brent Saunders, Actavis CEO, and David Pyott, Allergan chairman & CEO, about the growth and R&D budget of the combined companies going forward.

  • Actavis CEO: Allergan best run pharma company  Monday, 17 Nov 2014 | 9:30 AM ET

    CNBC's David Faber speaks to David Pyott, Allergan chairman & CEO, and Brent Saunders, Actavis CEO about their deal worth roughly $66 billion and what it means for shareholders.

  • *GlaxoSmithKline again leads index for best drug access. The contradictory advances and the problems facing the industry are evident at GlaxoSmithKline, which retained its long-standing top spot in the index, while simultaneously featuring in a major bribery scandal in China. "Corruption is terrible, but it also takes attention away from the fact that these...